2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-4-methyl-1,3-thiazole-5-carboxamide | 1021185-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-4-methyl-1,3-thiazole-5-carboxamide
• CAS: 1021185-50-1
• 化学式: C₁₈H₂₀N₄O₂S
• 分子量: 356.448
• InChiKey: AUHLOYCCRYLNLD-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  乙酰乙酰胺 、 (3S)-3-(1H-indol-3-ylmethyl)morpholine-4-carbothioamide 在 溴 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.03h， 以34%的产率得到2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-4-methyl-1,3-thiazole-5-carboxamide
  参考文献：
  名称：

  WO2008/47109

  摘要：

  公开号：

文献信息

• Thiazole Derivatives as Kinase Inhibitors
  申请人：Alexander Rikki Peter

  公开号：US20100298310A1

  公开（公告）日：2010-11-25

  A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  一系列噻唑衍生物，在2-位置被取代的吗啉-4-基团选择性地抑制PI3激酶酶，因此在医学上具有益处，例如在炎症，自身免疫，心血管，神经退行性，代谢，肿瘤，疼痛或眼科疾病的治疗中。
• Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
  申请人：Katsikis Peter D.

  公开号：US20110135655A1

  公开（公告）日：2011-06-09

  The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta.
• Compositions and Methods for Preventing or Treating Influenza Virus Infection
  申请人：Katsikis Peter D.

  公开号：US20120184519A1

  公开（公告）日：2012-07-19

  The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta.
• Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication
  申请人：Katsikis Peter D.

  公开号：US20130116267A1

  公开（公告）日：2013-05-09

  The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes a method of inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HTV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K P110 delta.
• US8168634B2
  申请人：——

  公开号：US8168634B2

  公开（公告）日：2012-05-01